Komori
Daito Pharmaceutical (4577) · TargetAdvancedLatest Financial results briefing materials (2026-10-14): "Other"

Management metrics for strengthening earnings power and the management structure

First written in FY2018. 8 of 25 entries say "Advanced", first in FY2019. Latest entry: 2026-10-14.

25entries
9years
6from disclosures
Share on X
How it moved
ProgressHeldSoftenedWorseAdvancedFY2019 – FY2022-Q3OtherFY2023-Q1 – FY2024-Q32018: 120182019: 120192020: 120202021: 120212022: 420222023: 420232024: 320242025: 220252026: 82026
Same theme, other companies
Improving Comprehensive Management Indicators Through Profit Margin on Sales, Equity Ratio and ROEA theme 19 companies write about · 0 as a headwind · 19 as a tailwind

The whole theme swung hardest in 2018: 2 of 14 companies on the "Worse" side.

2 other companies' latest entry also says "Other".

Ridges = years it wrote progress, valleys = years it wrote worse. Most hopeful companies at the back. Drag to turn, scroll to zoom, right-drag to pan. On a phone, two fingers turn and pinch to zoom; one finger scrolls the page.
Showing 14 of the 19 companies compared. The sentences above are computed from all 19.
Full recordFilings, disclosures and news, newest first
  1. FY2026AdvancedAnnual report

    「Operating profit was ¥3,637 million, up 38.8% from the previous fiscal year; ordinary profit was ¥3,812 million, up 40.9%; and net income attributable to owners of the parent was ¥3,161 million, up 65.7%.」

    For the metrics measuring earnings power and the management structure, operating income, ordinary income and net income attributable to owners of the parent increased from the previous year, while ROE improved from 3.7% to 6.0%.
  2. FY2026-H1AdvancedAnnual report

    「As a result, net sales for the current consolidated fiscal year were ¥25,141 million, up 2.3% year on year. Although selling, general and administrative expenses increased mainly due to higher research and development expenses and fees paid, a substantial improvement in inventory write-downs resulted in operating income of ¥1,627 million, up 10.6% year on year, ordinary income of ¥1,764 million, up 20.0%, and interim net income attributable to owners of the parent of ¥1,233 million, up 35.8%, marking the first profit increase in four periods.」

    In addition to net sales, operating income, ordinary income and interim net income attributable to owners of the parent increased year on year, marking the first profit increase in four periods.
  3. FY2025Updated full-year results reflecting higher sales and lower profitAnnual report

    「As a result, net sales for the current consolidated fiscal year were ¥50,643 million, up 8.0% from the previous fiscal year. Although higher net sales led to higher profit, operating income was ¥2,619 million, down 32.7% year on year, ordinary income was ¥2,705 million, down 31.0%, and net income attributable to owners of the parent was ¥1,908 million, down 42.1%, due mainly to higher depreciation and amortization, changes in the product mix and increased write-downs of long-outstanding inventory.」

    Full-year net sales increased, while operating income, ordinary income and net income attributable to owners of the parent all declined, updating the actual results for the earnings-power metrics.
  4. FY2025-H1Increase in Sales and Decline in ProfitsAnnual report

    「As a result, net sales for the interim consolidated accounting period were ¥24,584 million, up 2.0% year on year. Although net sales increased, operating income was ¥1,471 million, down 35.7% year on year, ordinary income was ¥1,470 million, down 36.5%, and interim net income attributable to owners of the parent was ¥908 million, down 41.5%, due mainly to higher depreciation and amortization, the effects of inventory valuation and higher raw material costs resulting from higher raw material prices, primarily because of the weaker yen.」

    Interim net sales increased 2.0% year on year, while operating income, ordinary income and interim net income attributable to owners of the parent decreased 35.7%, 36.5% and 41.5%, respectively.
  5. FY2024ReframedAnnual report

    「To strengthen its underlying earnings power in support of sustainable growth and pursue stable yet proactive shareholder returns, the group adopted net sales, EBITDA, the end-to-end ratio, CCC, ROIC, ROE and DOE as important management metrics.」

    The framework of metrics has changed from the previous measures, including net sales, operating margin, the equity ratio, the interest-bearing debt ratio and ROE, to one including EBITDA, the end-to-end ratio, CCC, ROIC, ROE and DOE.
  6. FY2024-Q3Flat sales and continued profit declineAnnual report

    「As a result, net sales for the first nine months of the current consolidated fiscal year were ¥34,662 million, up 0.3% year on year. Although net sales were almost flat, operating income was ¥3,105 million, down 24.4% year on year, ordinary income was ¥3,122 million, down 23.4%, and quarterly net income attributable to owners of the parent was ¥2,339 million, down 12.1%, due mainly to higher raw material costs resulting from the weaker yen and higher research and development expenses.」

    Net sales were almost flat, up 0.3% year on year, while operating income, ordinary income and quarterly net income attributable to owners of the parent all declined year on year.
  7. FY2024-Q2Sales growth and profit decline continueAnnual report

    「As a result, revenue for the six months ended the second quarter of the current consolidated fiscal year was ¥24,110 million, up 3.2% year on year. Although revenue increased, operating profit was ¥2,289 million, down 19.0% year on year, ordinary profit was ¥2,314 million, down 15.9%, and profit attributable to owners of the parent was ¥1,552 million, down 11.9%, mainly due to higher raw material costs and increased research and development expenses.」

    Net sales increased 3.2% year on year, while operating income, ordinary income and quarterly net income attributable to owners of the parent decreased 19.0%, 15.9% and 11.9%, respectively.
  8. FY2024-Q1Sales growth and profit decline continueAnnual report

    「As a result, net sales for the first six months of the current consolidated fiscal year were ¥12,178 million, up 1.1% year on year. Although net sales increased, operating income was ¥1,080 million, down 28.0% year on year, ordinary income was ¥1,092 million, down 26.0%, and quarterly net income attributable to owners of the parent was ¥683 million, down 27.7%, due mainly to higher raw material costs resulting from higher raw material prices, primarily because of the weaker yen, as well as higher research and development expenses.」

    Net sales increased 1.1% year on year, while operating income, ordinary income and quarterly net income attributable to owners of the parent decreased 28.0%, 26.0% and 27.7%, respectively.
  9. FY2023Updated full-year actual results and target metricsAnnual report

    「The plan for the current fiscal year was consolidated operating income of ¥4,500 million and consolidated net income of ¥3,200 million. Actual results were consolidated operating income of ¥5,207 million, consolidated net income of ¥3,600 million and consolidated ROE of 7.3%.」

    The plan and actual results for the current fiscal year were updated for the metrics subject to performance-linked compensation. Operating income and net income exceeded plan, while ROE was 7.3%.
  10. FY2023-Q3RestatedAnnual report

    「As a result, net sales for the first nine months of the current consolidated fiscal year were ¥34,570 million, up 2.9% year on year. Although higher net sales led to higher profit, operating income was ¥4,106 million, down 27.3% year on year, ordinary income was ¥4,077 million, down 29.6%, and quarterly net income attributable to owners of the parent was ¥2,660 million, down 33.1%, due mainly to higher raw material costs and electricity charges resulting from the weaker yen and higher energy resource prices, as well as increases in depreciation and amortization and research and development expenses.」

    The combination of higher net sales and lower operating income, ordinary income and quarterly net income attributable to owners of the parent continued from the previous quarter.
  11. FY2023-Q2Sales growth and profit decline continueAnnual report

    「As a result, net sales for the first six months of the current consolidated fiscal year were ¥23,367 million, up 4.0% year on year. Although higher net sales led to higher profit, operating income was ¥2,826 million, down 27.1% year on year, ordinary income was ¥2,752 million, down 30.9%, and quarterly net income attributable to owners of the parent was ¥1,762 million, down 36.5%, due mainly to higher raw material costs and electricity charges resulting from the weaker yen and higher energy resource prices, as well as increases in depreciation and amortization and research and development expenses.」

    Net sales increased 4.0% year on year, while operating income, ordinary income and quarterly net income attributable to owners of the parent decreased 27.1%, 30.9% and 36.5%, respectively.
  12. FY2023-Q1Higher sales alongside lower profitAnnual report

    「As a result, net sales for the first six months of the current consolidated fiscal year were ¥12,041 million, up 2.5% year on year. Although higher net sales led to higher profit, operating income was ¥1,501 million, down 36.4% year on year, ordinary income was ¥1,475 million, down 39.0%, and quarterly net income attributable to owners of the parent was ¥946 million, down 48.2%, due mainly to higher raw material costs resulting from higher raw material prices, primarily because of the weaker yen, as well as increases in depreciation and amortization and research and development expenses.」

    Net sales increased 2.5% year on year, while operating income, ordinary income and quarterly net income attributable to owners of the parent decreased 36.4%, 39.0% and 48.2%, respectively.
  13. FY2022ReframedAnnual report

    「Targets for the fiscal year ending May 2025 ・Consolidated net sales ¥52,000 million* ・Consolidated operating income ¥6,000 million ・Consolidated operating margin 11.5%」

    The targets were updated from the previous targets for the fiscal year ending May 2023 to the revised rolling targets for the fiscal year ending May 2025. The net sales target was changed from ¥53,000 million to ¥52,000 million, while the operating income target was changed to ¥6,000 million and the operating margin target to 11.5%; the previous ROE target is no longer included.
  14. FY2022-Q3AdvancedAnnual report

    「As a result, performance for the first nine months of the current consolidated fiscal year consisted of net sales of ¥33,583.023 million, operating income of ¥5,646.028 million, up 5.8% year on year, ordinary income of ¥5,794.485 million, up 6.9%, and quarterly net income attributable to owners of the parent of ¥3,978.141 million, up 7.5%.」

    Operating income, ordinary income and quarterly net income attributable to owners of the parent increased year on year for the first nine months.
  15. FY2022-Q2AdvancedAnnual report

    「As a result, performance for the first six months of the current consolidated fiscal year consisted of net sales of ¥22,463.211 million, operating income of ¥3,877.169 million, up 10.4% year on year, ordinary income of ¥3,981.467 million, up 12.0%, and quarterly net income attributable to owners of the parent of ¥2,777.074 million, up 14.6%.」

    Operating income, ordinary income and quarterly net income attributable to owners of the parent for the first six months increased 10.4%, 12.0% and 14.6%, respectively, year on year.
  16. FY2022-Q1AdvancedAnnual report

    「As a result, performance for the first quarter of the current consolidated fiscal year consisted of net sales of ¥11,746.666 million, operating income of ¥2,360.375 million, up 21.2% year on year, ordinary income of ¥2,419.744 million, up 23.1%, and quarterly net income attributable to owners of the parent of ¥1,825.087 million, up 38.1%.」

    Operating income, ordinary income and quarterly net income attributable to owners of the parent for the first quarter increased 21.2%, 23.1% and 38.1%, respectively, year on year.
  17. FY2020AdvancedAnnual report

    「Targets for the fiscal year ending May 2023 ・Consolidated net sales ¥53,000 million ・Consolidated operating income ¥5,500 million ・Consolidated operating margin 10.4% ・Consolidated ROE 8.0% or higher」

    New numerical targets have been set for net sales, operating income, operating margin and ROE, with the fiscal year ending May 2023 as the deadline, as important management metrics.
  18. FY2019AdvancedAnnual report

    「The plans for these metrics for the current fiscal year were consolidated net sales of ¥40,800 million, consolidated operating income of ¥4,300 million and consolidated net income of ¥3,100 million. Actual results were consolidated net sales of ¥41,134 million, consolidated operating income of ¥4,547 million, consolidated net income of ¥3,513 million and consolidated ROE of 11.4%.」

    The plan and actual results for the current fiscal year are compared specifically for the first time for the management metrics. Net sales, operating income and consolidated net income all exceeded plan.
  19. FY2018First statedAnnual report

    「From the perspective of securing the earnings power needed to support sustainable growth and strengthening the management structure, the group regards net sales, operating income and margin, the equity ratio, the interest-bearing debt ratio, and return on equity (ROE), among others, as important management metrics.」

    Net sales, operating margin, the equity ratio, the interest-bearing debt ratio and ROE, among others, are explicitly identified as important management metrics for the first time. No specific numerical targets are provided.
Moved together

"Reducing the interest-bearing debt ratio and strengthening equity capital" moved the same way as this thread, in the same document, in 7 of its 25 moves.

755554★123456
  1. ★This thread
  2. 1Reducing the interest-bearing debt ratio and strengthening equity capital7×
  3. 2Expansion and Rationalization of Production and R&D Facilities5×
  4. 3Risk of fluctuations in raw-material and procurement prices5×
  5. 4Risks Related to Interest-Bearing Debt, Interest Rates and Financial Covenants5×
  6. 5Customer Credit Risk5×
  7. 6Expected Expansion of the Generic Drug Market4×

★ is this thread; numbers match the list above. The number on a line is how many documents both moved the same way in; lines between the other threads count the documents they moved together in too. Threads that move together often sit closer.

When this could move next
No upcoming earnings preview for Daito Pharmaceutical yet. It last moved in the Financial results briefing materials of 2026-10-14: "Other".
News
No news is linked to this thread yet. When an article touches it, it will appear here by date.
Management metrics for strengthening earnings power and the management structure | Daito Pharmaceutical Co.,Ltd. (4577) | Komori